NOS2 and myeloid sarcoma: Furthermore, in the case of c.660 T > C—GPX4 (rs713041) and c.1823 C > T—NOS2 (rs2297518), the T/T–C/C (Crude OR 3.864; 1.607–9.295 95% CI; p < 0.01) and T/C–C/C (Crude OR 1.950; 1.157–3.289 95% CI; p < 0.05) combined genotypes were associated with an elevated risk of MS development.